BORDEAUX, France, May 25, 2026
TreeFrog Therapeutics announced new preclinical data showing that its investigational 3D neural microtissue cell therapy TFG-001 demonstrated rapid dopamine release, extensive brain reinnervation, and accelerated motor recovery across advanced translational models of Parkinson’s disease. The findings will be presented at the 7th World Parkinson’s Conference and further strengthen the company’s position that TFG-001 could emerge as a best-in-class regenerative cell therapy for neurodegenerative disorders involving dopaminergic neuron loss.
TFG-001 Demonstrates Rapid Dopamine Release and Brain Reinnervation
According to the company, TFG-001 was specifically engineered to overcome one of the biggest biological challenges in Parkinson’s disease treatment — restoring functional neural connections through reinnervation. In Parkinson’s disease, up to 60–80% of dopamine-producing neurons are already lost before motor symptoms appear, severely damaging the nigrostriatal pathway responsible for movement control. While existing therapies such as levodopa temporarily replace dopamine chemically, they do not rebuild the damaged neural circuitry required for long-term functional recovery.
TreeFrog reported that TFG-001 demonstrated dopamine release within just 48 hours after transplantation, significantly faster than benchmark cell therapies that reportedly require nearly four weeks to achieve similar activity. The therapy also showed extensive graft-derived reinnervation in advanced in vivo Parkinson’s disease models, indicating strong integration of transplanted neural tissue into the host brain. Researchers observed that the therapy’s pre-organized 3D dopaminergic network, containing both neural progenitors and mature neurons, may allow more efficient tissue integration compared with conventional single-cell suspension therapies.
Preclinical Models Show Faster Functional Recovery
Advertisement
The company stated that preclinical Parkinson’s disease models treated with TFG-001 achieved functional motor recovery in approximately 13 weeks, faster than previously reported benchmark cell therapies that typically require between 17 and 28 weeks. In addition to motor improvement, TreeFrog highlighted evidence supporting sustained neural repair and enhanced dopaminergic signaling within affected brain regions.
Professor Stéphane Palfi, Head of Neurosurgery at Henri Mondor Medical Center and Paris University, stated that the findings demonstrated “robust, extensive reinnervation both in vitro and in vivo” across multiple advanced translational models. He added that the 3D iPSC-derived neural microtissue approach has the potential to significantly improve neural engraftment and therapeutic outcomes in Parkinson’s disease patients.
Scalable Manufacturing Platform Supports Future Clinical Development
Beyond biological performance, TreeFrog emphasized the scalability advantages of its proprietary C-Stem™ manufacturing platform, a closed bioreactor-based capsule technology designed for large-scale cell expansion and differentiation under GMP-compliant conditions. The company believes scalable manufacturing will be essential for addressing the substantial unmet need in Parkinson’s disease, which affects an estimated 1.3 million patients in Europe and 1 million patients in the United States.
TreeFrog stated that TFG-001 is expected to be ready for a Clinical Trial Application (CTA) in 2027 and confirmed that it is actively exploring co-development and commercialization opportunities for the therapy. The company also noted that the ongoing development program positions TFG-001 as a potential next-generation regenerative medicine platform capable of restoring functional neuronal networks rather than simply replacing dopamine chemically.
The preclinical data will be presented during Poster Session 3 at the 7th World Parkinson’s Conference on May 27, 2026, under the abstract titled “Advancing neural microtissues toward a clinically viable cell therapy for Parkinson’s disease.”
Source: TreeFrog Therapeutics press release
